Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Curasen Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is assigned to a distinct examiner, ROZOF, TIMOTHY R, and is located in a distinct art unit. ROZOF, TIMOTHY R is the busiest examiner for the portfolio, with 1 pending office action.
The presence of a distinct art unit for the pending action shows a very focused prosecution effort. With only 1 pending office action in the entire portfolio, the company's current interaction with the patent office is limited to this single examiner. This means that ROZOF, TIMOTHY R is responsible for the review of the company's entire active biotechnology patent matter. This centralized structure allows the company to concentrate its resources on a specific technical challenge while navigating the examination process with one primary point of contact.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694362 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ROZOF, TIMOTHY R | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18694362 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ROZOF, TIMOTHY R | 1625 | §102§112DP | Non-Final OA | — | Pending | Mar 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial